380 related articles for article (PubMed ID: 31965018)
21. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Mizuno Y; Yamamotoya T; Nakatsu Y; Ueda K; Matsunaga Y; Inoue MK; Sakoda H; Fujishiro M; Ono H; Kikuchi T; Takahashi M; Morii K; Sasaki K; Masaki T; Asano T; Kushiyama A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546603
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
[TBL] [Abstract][Full Text] [Related]
23. Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Xu D; Murakoshi N; Tajiri K; Duo F; Okabe Y; Murakata Y; Yuan Z; Li S; Aonuma K; Song Z; Shimoda Y; Mori H; Sato A; Nogami A; Aonuma K; Ieda M
Clin Sci (Lond); 2021 Oct; 135(20):2409-2422. PubMed ID: 34386810
[TBL] [Abstract][Full Text] [Related]
24. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
25. Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
Tani S; Nagao K; Hirayama A
Clin Drug Investig; 2015 Dec; 35(12):823-31. PubMed ID: 26482071
[TBL] [Abstract][Full Text] [Related]
26. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
27. Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Guma M; Dadpey B; Coras R; Mikuls TR; Hamilton B; Quehenberger O; Thorisdottir H; Bittleman D; Lauro K; Reilly SM; Liu-Bryan R; Terkeltaub R
Arthritis Res Ther; 2022 Jul; 24(1):175. PubMed ID: 35879786
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
[TBL] [Abstract][Full Text] [Related]
29. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
30. Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease.
Schmidt HM; Wood KC; Lewis SE; Hahn SA; Williams XM; McMahon B; Baust JJ; Yuan S; Bachman TN; Wang Y; Oh JY; Ghosh S; Ofori-Acquah SF; Lebensburger JD; Patel RP; Du J; Vitturi DA; Kelley EE; Straub AC
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):769-782. PubMed ID: 33267657
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.
Shirakura T; Nomura J; Matsui C; Kobayashi T; Tamura M; Masuzaki H
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):831-8. PubMed ID: 27198514
[TBL] [Abstract][Full Text] [Related]
32. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Aksenov S; Peck CC; Eriksson UG; Stanski DR
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29488355
[TBL] [Abstract][Full Text] [Related]
33. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
Cicero AFG; Fogacci F; Cincione RI; Tocci G; Borghi C
Med Princ Pract; 2021; 30(2):122-130. PubMed ID: 33040063
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Bove M; Cicero AFG; Borghi C
Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
[TBL] [Abstract][Full Text] [Related]
35. Comparing the Effects of Febuxostat and Allopurinol in an Animal Model of Metabolic Syndrome.
Nadwa EH; Morcos GNB; Salama NM; Shafik AN
Pharmacology; 2021; 106(9-10):564-572. PubMed ID: 34182567
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors.
Xu X; Deng L; Nie L; Chen Y; Liu Y; Xie R; Li Z
Bioorg Med Chem Lett; 2019 Feb; 29(4):525-528. PubMed ID: 30630716
[TBL] [Abstract][Full Text] [Related]
37. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
38. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
39. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.
Malik UZ; Hundley NJ; Romero G; Radi R; Freeman BA; Tarpey MM; Kelley EE
Free Radic Biol Med; 2011 Jul; 51(1):179-84. PubMed ID: 21554948
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
